Education
About Us
Working with TipRanks
Follow Us
Precision BioSciences (DTIL)
NASDAQ:DTIL
DTIL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.61 - $15.97
Previous CloseN/A
Volume55.33K
Average Volume (3M)146.34K
Market Cap
$35.83M
Enterprise Value-$25.79M
Total Cash (Recent Filing)$116.68M
Total Debt (Recent Filing)$31.27M
Price to Earnings (P/E)2.4
Beta1.74
Next Earnings
May 07, 2025EPS Estimate
-1.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.89
Shares Outstanding10,481,931
10 Day Avg. Volume204,368
30 Day Avg. Volume146,342
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.56
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.64
Enterprise Value/Ebitda-1.37
Forecast
1Y Price Target
$41.33Price Target Upside779.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Precision BioSciences News
---
Bulls Say, Bears Say
Bulls Say
Duchenne Muscular Dystrophy TreatmentPrecision presented encouraging in vivo data from its wholly-owned preclinical muscle-targeted DNA excision program PBGENE-DMD, which demonstrates a highly-differentiated therapeutic approach in Duchenne muscular dystrophy.
Financial PositionWith a healthy balance sheet, multiple revenue-generating collaborations, and increasing momentum of its wholly-owned clinical and preclinical pipeline, Precision is well-positioned for significant near-term upside.
Gene Editing PipelineMultiple near-term catalysts across a broad in vivo gene editing pipeline should drive substantial upside.
Hepatitis B TreatmentPrecision's lead wholly-owned viral elimination program PBGENE-HBV has demonstrated the first-ever clinical proof-of-concept for an in vivo gene editing approach in chronic hepatitis B infection.
Bears Say
Patient Enrollment ChallengesThe trial's key enrollment criteria excludes patients with signs of hepatocellular carcinoma (HCC) and cirrhosis, potentially limiting patient eligibility.
Risks And ChallengesRisks include clinical development risk tied to the CAR T and gene editing programs, commercialization risk, reimbursement risk, capital markets and dilution risk, pricing risk, and clinical trial risk owing to the war in Eastern Europe.
---
Ownership Overview
4.50% Insiders
5.30% Mutual Funds
28.16% Other Institutional Investors
58.77% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
DTIL FAQ
What was Precision BioSciences’s price range in the past 12 months?
Precision BioSciences lowest stock price was $3.61 and its highest was $15.97 in the past 12 months.
What is Precision BioSciences’s market cap?
Precision BioSciences’s market cap is $35.83M.
When is Precision BioSciences’s upcoming earnings report date?
Precision BioSciences’s upcoming earnings report date is May 07, 2025 which is in 38 days.
How were Precision BioSciences’s earnings last quarter?
Precision BioSciences released its earnings results on Mar 26, 2025. The company reported -$2.22 earnings per share for the quarter, beating the consensus estimate of -$2.252 by $0.032.
Is Precision BioSciences overvalued?
According to Wall Street analysts Precision BioSciences’s price is currently Undervalued.
Does Precision BioSciences pay dividends?
Precision BioSciences does not currently pay dividends.
What is Precision BioSciences’s EPS estimate?
Precision BioSciences’s EPS estimate is -1.56.
How many shares outstanding does Precision BioSciences have?
Precision BioSciences has 10,481,931 shares outstanding.
What happened to Precision BioSciences’s price movement after its last earnings report?
Precision BioSciences reported an EPS of -$2.22 in its last earnings report, beating expectations of -$2.252. Following the earnings report the stock price went down -11.002%.
Which hedge fund is a major shareholder of Precision BioSciences?
Currently, no hedge funds are holding shares in DTIL
---
Precision BioSciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.33 (779.36% Upside)
$41.33 (779.36% Upside)
Hedge Fund Trend
Decreased
By 426.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $108.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.33%
12-Months-Change
Fundamentals
Return on Equity
19.05%
Trailing 12-Months
Asset Growth
-14.64%
Trailing 12-Months
Company Description
Precision BioSciences
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
---
DTIL Stock 12 Month Forecast
Average Price Target
$41.33
▲(779.36% Upside)
Technical Analysis
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering DTIL
1 Year
1 Year Success Rate
0/23 ratings generated profit
1 Year Average Return
-49.83%
reiterated a buy rating 2 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -49.83% per trade.
---